Molecular Detection and Diagnostics Core

项目总结/摘要（分子检测和诊断核心） Tulane COBRE用于心脏代谢疾病的临床和转化研究2期应用 旨在进一步发展和加强杜兰大学的临床和转化研究基础设施 并不断扩大和支持具有临床和翻译专业知识的研究者的临界质量 心脏代谢疾病的研究。新提出的分子检测和诊断核心（MDDC） 将支持研究项目负责人（RPL）、试点项目负责人（PPL）、其他COBRE研究人员， 通过提供尖端仪器，创新技术和 方法，和多学科研究的专业知识，包括生物化学，生物医学工程， 分析化学，蛋白质组学，纳米技术和质谱（MS），以推进其临床和 心脏代谢疾病的病因学、预防、诊断和治疗的转化研究。的 MDDC将开发和调整基于纳米技术的综合战略和其他创新技术， 鉴定用于早期疾病检测、预后评估和实时监测的新型生物标志物， 治疗反应以及了解心脏代谢疾病的分子机制。MDDC 旨在促进跨越分析化学-生物学界面的研究，使研究人员能够 确定和解决临床和转化科学中重要的跨学科研究问题， 心脏代谢疾病根据我们团队的专业知识，MDDC将为COBRE调查人员提供 最先进的分析技术，如MS和基于微阵列的蛋白质组学的培训和服务 和芯片上器官等，用于分析组织和生物流体样品的复杂蛋白质组。的 MDDC还将确定适当的现有分析方法，并采用新开发的方法， 没有成熟的技术。MDDC将设在杜兰大学中心内 用于细胞和分子诊断，已在传染病和慢性疾病方面建立了良好的基础 research.在COBRE第二阶段，MDDC将提供尖端的工具和方法， 支持项目2和项目3的研究授权书开展各自的研究项目。此外，MDDC将 为项目1和4的RPL提供专家咨询和最先进的技术，以开发R01 应用于进一步研究APOL 1对慢性肾脏疾病进展的分子机制， 钾摄入量对降低血压的作用。拟议的MDDC将加强互动， COBRE，非COBRE和参与分子研究的外部研究者之间的合作 心脏代谢疾病由于MDDC是COBRE计划的关键组成部分，我们的长期目标是 将MDDC发展成为一个可持续的资源，服务于从基础科学到转化研究的所有阶段， 从临床科学到人口科学，提供广泛的最先进的细胞 分子分析服务。

PROJECT SUMMARY/ABSTRACT (Molecular Detection and Diagnostics Core) The Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases Phase 2 application aims to further develop and strengthen the clinical and translational research infrastructure at Tulane University and to continuously expand and support a critical mass of investigators with expertise in clinical and translational research in cardiometabolic diseases. The newly proposed Molecular Detection and Diagnostics Core (MDDC) will support the Research Project Leaders (RPLs), Pilot Project Leaders (PPLs), other COBRE investigators and collaborators at Tulane University by providing cutting-edge instruments, innovative technologies and methodologies, and expertise in multidisciplinary research including biochemistry, biomedical engineering, analytical chemistry, proteomics, nanotechnology, and mass spectrometry (MS) to advance their clinical and translational research in the etiology, prevention, diagnosis, and treatment of cardiometabolic disease. The MDDC will develop and adapt integrated nanotechnology-based strategies and other innovative technologies to identify novel biomarkers for early disease detection, prognostic evaluation, and the real-time monitoring of treatment responses as well as to understand the molecular mechanisms of cardiometabolic disease. The MDDC seeks to catalyze research that spans the analytical chemistry-biology interface, empowering investigators to identify and solve important interdisciplinary research questions in the clinical and translational sciences of cardiometabolic disease. Based on our team's expertise, the MDDC will provide COBRE investigators with training and services in state-of-the-art analytical technologies such as MS and microarray-based proteomics and organ-on-a-chip, among others, for the analysis of complex proteomes of tissue and biofluid samples. The MDDC will also identify appropriate existing analytical methods as well as adapt newly developed methods, often not available in the form of mature technologies. The MDDC will be housed within the Tulane University Center for Cellular and Molecular Diagnostics, which has been well established for infectious and chronic disease research. During the COBRE Phase 2, the MDDC will provide cutting-edge instruments and methodological support for RPLs of Projects 2 and 3 to conduct their individual research projects. In addition, the MDDC will provide expert consultation and state-of-the-art technologies for RPLs of Projects 1 and 4 to develop R01 applications to further investigate molecular mechanism of APOL1 on chronic kidney disease progression and potassium intake on blood pressure reduction. The proposed MDDC will enhance the interactions and collaborations among COBRE, non-COBRE and external investigators involved in molecular studies of cardiometabolic disease. Since the MDDC is a critical component of the COBRE program, our long-term goal is to grow MDDC into a sustainable resource that serves all phases of translational research, from basic science to clinical science to population science at Tulane University by providing a broad range of state-of-the-art cellular and molecular analytical services.